HRMY
Harmony Biosciences Holdings
NASDAQ · Pharmaceuticals
$37.27
+0.86 (+2.36%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 711.36M | 535.78M | 495.90M | 502.35M | 437.14M |
| Net Income | 144.80M | 98.16M | 96.19M | 88.37M | 76.03M |
| EPS | — | — | — | — | — |
| Profit Margin | 20.4% | 19.3% | 19.4% | 17.6% | 17.4% |
| Rev Growth | +32.8% | +32.8% | +9.0% | +14.6% | +13.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 229.51M | 229.51M | 602.53M | 560.81M | 468.91M |
| Total Equity | 843.80M | 843.80M | 1.64B | 1.49B | 1.38B |
| D/E Ratio | 0.27 | 0.27 | 0.37 | 0.38 | 0.34 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 213.59M | 152.83M | 152.11M | 150.20M | 134.03M |
| Free Cash Flow | — | — | 107.84M | 92.06M | 66.59M |